Search Results

There are 8180182 results for: content related to: Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease

  1. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  2. Improving l-dopa therapy: The development of enzyme inhibitors

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 103–113, Oscar S. Gershanik

    Version of Record online : 21 OCT 2014, DOI: 10.1002/mds.26050

  3. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Version of Record online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  4. Effects of rasagiline on olfactory function in patients with Parkinson's disease

    Movement Disorders

    Volume 28, Issue 14, December 2013, Pages: 2023–2027, Antje Haehner, Thomas Hummel, Martin Wolz, Lisa Klingelhöfer, Mareike Fauser, Alexander Storch and Heinz Reichmann

    Version of Record online : 4 NOV 2013, DOI: 10.1002/mds.25661

  5. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial

    Movement Disorders

    Volume 31, Issue 5, May 2016, Pages: 709–714, Daniel Weintraub, Robert A. Hauser, Jordan J. Elm, Fernando Pagan, Matthew D. Davis, Azhar Choudhry and for the MODERATO Investigators

    Version of Record online : 31 MAR 2016, DOI: 10.1002/mds.26617

  6. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Version of Record online : 6 JUN 2014, DOI: 10.1002/mds.25914

  7. Long-term effects of rasagiline and the natural history of treated Parkinson's disease

    Movement Disorders

    Volume 31, Issue 10, October 2016, Pages: 1489–1496, Olivier Rascol, Robert A. Hauser, Fabrizio Stocchi, Cheryl J. Fitzer-Attas, Yulia Sidi, Victor Abler, C. Warren Olanow and for the AFU Investigators

    Version of Record online : 19 JUL 2016, DOI: 10.1002/mds.26724

  8. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease

    European Journal of Neurology

    Volume 19, Issue 2, February 2012, Pages: 258–264, E. Tolosa and M. B. Stern

    Version of Record online : 5 AUG 2011, DOI: 10.1111/j.1468-1331.2011.03484.x

  9. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy

    Movement Disorders

    Volume 30, Issue 11, 15 September 2015, Pages: 1528–1538, Werner Poewe, Philipp Mahlknecht and Florian Krismer

    Version of Record online : 30 JUL 2015, DOI: 10.1002/mds.26334

  10. You have full text access to this OnlineOpen article
    A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

    European Journal of Neurology

    Volume 22, Issue 8, August 2015, Pages: 1184–1191, P. Barone, G. Santangelo, L. Morgante, M. Onofrj, G. Meco, G. Abbruzzese, U. Bonuccelli, G. Cossu, G. Pezzoli, P. Stanzione, L. Lopiano, A. Antonini and M. Tinazzi

    Version of Record online : 12 MAY 2015, DOI: 10.1111/ene.12724

  11. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  12. Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

    The Journal of Clinical Pharmacology

    Volume 50, Issue 12, December 2010, Pages: 1420–1428, Tamar Goren, Liat Adar, Nissim Sasson and Yoni M. Weiss

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010369674

  13. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease

    Movement Disorders

    Volume 30, Issue 13, November 2015, Pages: 1825–1830, Thien Thien Lim, Benzi M. Kluger, Ramon L. Rodriguez, Irene A. Malaty, Rafael Palacio Jr., Oluwadamilola O. Ojo, Shnehal Patel, Yogesh Gujrati, Benjamin Nutter, Camille Swartz, Carol Hennessy and Hubert H. Fernandez

    Version of Record online : 14 NOV 2015, DOI: 10.1002/mds.26429

  14. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease

    Movement Disorders

    C. Warren Olanow, Karl Kieburtz, Mika Leinonen, Lawrence Elmer, Nir Giladi, Robert A. Hauser, Olga S. Klepiskaya, David L. Kreitzman, Mark F. Lew, David S. Russell, Shaul Kadosh, Pninit Litman, Hadas Friedman, Nurit Linvah and for the P2B Study Group

    Version of Record online : 3 APR 2017, DOI: 10.1002/mds.26941

  15. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS

    Movement Disorders

    Volume 30, Issue 4, April 2015, Pages: 589–592, Werner Poewe, Robert A. Hauser and Anthony Lang

    Version of Record online : 27 DEC 2014, DOI: 10.1002/mds.26124

  16. Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 10, October 2004, Pages: 1295–1305, Dr. John J. Thébault, Dr. Michel Guillaume and Dr. Ruth Levy

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.24.14.1295.43156

  17. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133

  18. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  19. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

    International Journal of Clinical Practice

    Volume 60, Issue 2, February 2006, Pages: 215–221, F. Stocchi

    Version of Record online : 1 FEB 2006, DOI: 10.1111/j.1742-1241.2006.00806.x

  20. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

    Movement Disorders

    Volume 19, Issue 8, August 2004, Pages: 916–923, Matthew B. Stern, Kenneth L. Marek, Joseph Friedman, Robert A. Hauser, Peter A. LeWitt, Daniel Tarsy and C. Warren Olanow

    Version of Record online : 27 APR 2004, DOI: 10.1002/mds.20145